Cargando…
Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease worldwide. The renal phenotype is characterized by progressive cystic enlargement of the kidneys leading to a decline in renal function, hypertension and often end-stage renal disease (ESRD)....
Autores principales: | Müller, Roman-Ulrich, Haas, Christian S, Sayer, John A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798152/ https://www.ncbi.nlm.nih.gov/pubmed/29423204 http://dx.doi.org/10.1093/ckj/sfx071 |
Ejemplares similares
-
Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
por: Gilbert, Rodney D., et al.
Publicado: (2017) -
Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
por: Bellos, Ioannis
Publicado: (2021) -
Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
por: Kim, Yaerim, et al.
Publicado: (2023) -
Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
por: Gkekas, Eleftherios, et al.
Publicado: (2022) -
Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease
por: Magistroni, Riccardo
Publicado: (2018)